TPG Scores $5 Billion Gain in Three Years on Par Pharma Sale
This article is for subscribers only.
TPG Capital will score at least a $5 billion profit, or about 6.5 times its investment, from its sale of Par Pharmaceutical Holdings Inc. to Endo International Plc after holding the company for less than three years.
TPG and co-investors put more than $800 million in the drugmaker from 2012 to 2014, according to regulatory filings. The owners will get about $5.7 billion in cash and stock from the sale to Dublin-based Endo announced Monday, after receiving a $494 million dividend in February, the filings show.